WuXi Biologics (Cayman) Inc. (2269)

Basic

  • Market Cap

    HK$124.54B

  • EV

    HK$122.33B

  • Shares Out

    4,243.36M

  • Revenue

    CN¥16.55B

  • Employees

    12,397

Margins

  • Gross

    41.51%

  • EBITDA

    29.17%

  • Operating

    25.18%

  • Pre-Tax

    29.94%

  • Net

    25.08%

  • FCF

    -2.14%

Returns (5Yr Avg)

  • ROA

    4.85%

  • ROE

    11.13%

  • ROCE

    9.31%

  • ROIC

    10.63%

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • EV/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    HK$51.07

  • P/E

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • EV/FCF

    —

Per Share

  • Rev

    CN¥3.98

  • Earnings (Dil)

    CN¥0.95

  • FCF

    -CN¥0.07

  • Book Value

    CN¥8.88

Growth (CAGR)

  • Rev 3Yr

    56.48%

  • Rev 5Yr

    52.32%

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    44.09%

  • Dil EPS 5Yr

    55.24%

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    28.17%

  • EBITDA Fwd 2Yr

    16.16%

  • EPS Fwd 2Yr

    21.03%

  • EPS LT Growth Est

    15.58%

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

Select a metric from the list below to chart it

Dec '14
Dec '16
Dec '18
Dec '20
Dec '22
Metric
Dec '14
Dec '15
Dec '16
Dec '17
Dec '18
Dec '19
Dec '20
Dec '21
Dec '22
LTM

Total Revenues

2,534.5

3,983.7

5,612.4

10,290.1

15,268.7

16,554.3

Total Revenues % Chg.

56.6%

57.2%

40.9%

83.3%

48.4%

26.5%

Cost of Goods Sold, Total

1,516.7

2,325.0

3,079.4

5,461.2

8,544.6

9,682.8

Gross Profit

1,017.8

1,658.7

2,533.0

4,828.9

6,724.0

6,871.4

Selling General & Admin Expenses, Total

270.2

444.4

605.9

1,000.6

1,432.5

1,630.3

Provision for Bad Debts

55.9

6.7

116.1

132.4

260.0

326.1

R&D Expenses

169.3

259.7

303.7

501.6

682.8

753.1

Other Operating Expenses

—

—

5.0

24.3

-1.5

-6.6

Other Operating Expenses, Total

495.4

710.7

1,030.6

1,658.8

2,373.8

2,702.9

Operating Income

522.4

948.0

1,502.3

3,170.1

4,350.2

4,168.5

Interest Expense, Total

—

-19.6

-42.7

-39.2

-64.4

-120.5

Interest And Investment Income

88.8

75.8

80.9

58.0

115.8

138.3

Net Interest Expenses

88.8

56.1

38.1

18.8

51.4

17.8

Income (Loss) On Equity Invest.

—

-3.1

2.6

—

—

—

Currency Exchange Gains (Loss)

7.3

8.1

-91.3

-32.6

417.2

479.2

Other Non Operating Income (Expenses)

118.5

114.0

142.5

171.4

159.6

113.3

EBT, Excl. Unusual Items

736.9

1,123.1

1,594.3

3,327.7

4,978.3

4,778.8

Gain (Loss) On Sale Of Investments

0.8

3.5

371.4

665.4

379.4

185.2

Other Unusual Items

—

—

—

—

—

-7.4

EBT, Incl. Unusual Items

737.7

1,126.6

1,965.8

3,993.1

5,357.8

4,956.6

Income Tax Expense

107.3

116.3

273.1

484.5

807.9

690.1

Earnings From Continuing Operations

630.5

1,010.3

1,692.7

3,508.6

4,549.9

4,266.5

Minority Interest

0.1

3.5

-3.8

-120.1

-129.6

-114.6

Net Income

630.6

1,013.8

1,688.9

3,388.5

4,420.3

4,151.9

Net Income to Common Incl Extra Items

630.6

1,013.8

1,688.9

3,388.5

4,420.3

4,151.9

Net Income to Common Excl. Extra Items

630.6

1,013.8

1,688.9

3,388.5

4,420.3

4,151.9

Total Shares Outstanding

3,677.8

3,883.6

4,084.8

4,224.4

4,225.3

4,248.5

Weighted Avg. Shares Outstanding

3,631.6

3,717.1

3,953.0

4,173.7

4,172.7

4,163.9

Weighted Avg. Shares Outstanding Dil

3,941.6

3,997.1

4,209.2

4,421.8

4,375.9

4,357.7

EPS

0.2

0.3

0.4

0.8

1.1

1.0

EPS Diluted

0.2

0.3

0.4

0.8

1.0

0.9

EBITDA

663.9

1,141.3

1,771.2

3,622.3

5,068.8

4,828.3